Welcome to our dedicated page for Tandem Diabetes SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tandem Diabetes Care, Inc. (NASDAQ: TNDM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tandem Diabetes Care is a global insulin delivery and diabetes technology company whose common stock is registered under Section 12(b) of the Exchange Act and listed on the NASDAQ Global Market under the symbol TNDM.
Through this page, users can review current reports on Form 8-K that document material events such as quarterly earnings announcements, regulatory clearances, and board of director changes. Recent 8-K filings referenced by the company include reports on financial results for quarters ended during 2025 and the appointment of a new independent director to the board, along with related committee assignments and compensation details. Other 8-K filings describe FDA 510(k) clearance for the SteadiSet infusion set and similar operational milestones.
In addition to 8-Ks, Tandem Diabetes Care files annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide detailed information on its insulin delivery systems, financial condition, risk factors, and business strategy. These filings are important for understanding how the company’s pump portfolio, infusion sets, mobile applications, and cloud-based platforms contribute to its overall operations and financial results.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify information on revenue drivers, regulatory developments, and governance matters. The platform also surfaces insider transaction reports on Form 4 when available, allowing investors to monitor share transactions by directors and officers. Real-time updates from the SEC’s EDGAR system ensure that new Tandem Diabetes Care filings appear promptly, while AI-generated explanations make complex regulatory language more accessible.
SEC Form 4 filed on 06/18/2025 reveals that Tandem Diabetes Care, Inc. (TNDM) director Myoungil Cha acquired 1,749 shares of common stock on 06/16/2025 through the vesting and settlement of previously granted restricted stock units (RSUs) under the company’s 2013 Stock Incentive Plan. The conversion, reported with transaction code “M,” was executed at $0 cost to the insider and involved no open-market purchase or sale.
Following the transaction, Cha’s direct beneficial ownership rose from 11,950 to 13,699 shares. The RSU grant was originally awarded on 06/15/2022 and vests in three equal annual installments; the reported shares represent the second installment, with additional tranches scheduled for future anniversaries, subject to plan terms.
Key takeaways:
- Insider ownership increase: +1,749 shares, signalling continued alignment with shareholder interests.
- Routine equity compensation: Transaction stems from standard RSU vesting, not discretionary market activity.
- No cash proceeds or sales: Neutral impact on near-term share flow and insider liquidity.
Form 4 filing: On 18-Jun-2025 Tandem Diabetes Care (TNDM) reported that director Joao Paulo Falcao Malagueira acquired 1,749 common shares on 16-Jun-2025 through the automatic settlement of previously granted restricted stock units (RSUs). The RSUs were awarded on 15-Jun-2022 under the company’s 2013 Stock Incentive Plan and vest in three equal annual instalments. No cash consideration was paid (exercise price $0).
Following the conversion, the director’s direct ownership increases to 13,699 TNDM shares. The transaction is coded “M,” indicating a routine equity award vesting rather than an open-market trade, and leaves no remaining derivative securities from this grant. The filing does not signal any strategic or operational changes at the company.